The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., Apr. 21, 2:59 PM

Slide #25. uniQure N.V. Secondary Offering

Company: uniQure N.V. (NASDAQ:QURE)
Date announced: 4/7/2015
Shares Offered: 3,000,000
Date of Pricing: 4/9/2015
Price Per Share: $29.50
Secondary Offering Details: uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that it has commenced a follow-on public offering of 3,000,000 of its ordinary shares. All ordinary shares to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. - updated 4/10 - uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the pricing of its follow-on public offering of 3,000,000 ordinary shares at price to the public of $29.50 per ordinary share. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the follow-on public offering are expected to be approximately $82.4 million (76.5 million). In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. The offering is expected to close on or about April 15, 2015.

uniQure is engaged in the field of gene therapy and has developed the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. Co.'s first product, Glybera, was approved by the European Commission in October 2012 under circumstances for the treatment of a subset of patients with LPLD, a potentially life-threatening, orphan metabolic disease. Co. retains full commercial rights to Glybera in the United States.
Open the QURE Page at The Online Investor »

Company Name:  uniQure N.V.
Website:  www.uniqure.com
Sector:  Drugs & Pharmaceuticals
 

Open the QURE Page at The Online Investor (in a new window) »

April 21, 2015    2:59 PM Eastern
Quotes delayed 20 minutes


Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.